Table 1 Frequency of selected autoantibodies in the CSRG cohort
From: Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis
| Â | n | % | Numbers not tested |
|---|---|---|---|
CENP-B | 285 | 36% | 162 |
Centromere by IIF | 334 | 35% | 2 |
CENP-A | 275 | 34% | 162 |
Ro52/TRIM21 | 194 | 20% | 0 |
RNA polymerase III | 144 | 19% | 188 |
Topoisomerase I | 150 | 16% | 0 |
PM/Scl | 53 | 7% | 188 |
Ro60 | 53 | 6% | 0 |
U1 RNP | 59 | 6% | 0 |
Chromatin | 44 | 5% | 0 |
Sm | 39 | 4% | 0 |
SS-B/La | 26 | 3% | 0 |
Jo-I | 6 | 1% | 0 |
Ribosomal P | 14 | 1% | 0 |